Loading…
← CockpitCompetitor Analysis › 2268.HK WuXi XDC Cayman, Inc.Open in the cockpit ↗

WuXi XDC Cayman, Inc.2268.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Miscellaneous Commercial Services

Contract developer and manufacturer (CDMO) of antibody-drug conjugates, spun off from WuXi Biologics.

≈ A specialized CDMO focused on ADC cancer drugs, like a niche Lonza/CatalentMomentum strong 80
Mkt cap
$10.4B
US dollars, full cap
Free float
33%
of shares outstanding
$/day
$48.2M
20-day average traded
Fwd P/E
35.8×
forward earnings
ROIC−WACC
+14.3 pp
WACC 9.1%
Hurdle
-106 pp
Req g minus delivered
Next earnings
131 days
29 Mar 2027
Close · HKDHK$66.05
1D-2.1%
1W-8.3%
1M-12.9%
3M-2.9%
6M+19.8%
YTD+8.7%
1Y-4.0%
ATR %6.1%
52w lowhigh22.8% off high

What WuXi XDC Cayman does

Contract developer and manufacturer (CDMO) of antibody-drug conjugates, spun off from WuXi Biologics.

Customers pay fees for developing the manufacturing process, then for each batch of clinical and eventually commercial supply, so each project starts small and grows as the customer's drug advances. It handles the antibody, the toxin-linker and the final joining step under one roof.

In one line: A specialized CDMO focused on ADC cancer drugs, like a niche Lonza/Catalent.

Products and services

  • ADC process development
  • ADC commercial manufacturing
  • Bioconjugation services

Customers

  • Global biopharma companies developing ADC cancer d

Where it sits in the supply chain

  • Healthcare
  • Biopharma CDMO
  • Antibody-drug conjugate development…

What could go right

  • Global ADC drug pipeline growth
  • Biopharma outsourcing of specialty manufacturing

What could go wrong

  • Customer/pipeline concentration risk
  • US biosecurity/outsourcing policy risk

Moat: narrow (process know-how, customer qualification, scale). Specialized ADC bioconjugation expertise and capacity, with high switching costs once qualified.

Headquarters: Wuxi, China · Founded: 2021 · Employees: 2,662

Named competitors

WuXi XDC Cayman at a glance

Size WuXi XDC Cayman (2268.HK) is a Hong Kong Health Care company (Miscellaneous Commercial Services) with a market value of $10.4B, the 157th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$66.05 on 18 Nov 2026.

Performance Over six months the shares gained 19.8%, against +53.3% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 2nd lowest of 6 in its peer set.

Growth Revenue grew 41.5% over the last twelve months (peer median +5.5%); the operating margin is 27.7% (peer median 9.6%).

Valuation It trades at 35.8× forward earnings against a peer median of 26.2× (most expensive of 6).

Price implies For today's price to make sense, revenue must grow about 21% a year for seven years (Req g). Recent delivered growth is +126%, so the hurdle is -106 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 14.3 points above its cost of capital (9.1% WACC).

Next results Next results expected around 29 Mar 2027 (exchange calendar; dates can move).

Relative performance

7510012515021 May 202621 Aug 202618 Nov 2026Peer median 1502268.HK 114
Six months, rebased to 100: WuXi XDC Cayman against the median of its 5 peers (local-currency closes).

WuXi XDC Cayman financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$7.77BHK$6.45BHK$4.39BHK$2.35BHK$1.15B
Revenue growth—+47%+87%+104%—
Gross profitHK$2.84BHK$2.32BHK$1.34BHK$618MHK$304M
EBITDAHK$2.39BHK$1.93BHK$1.11BHK$476MHK$192M
Net incomeHK$1.74BHK$1.61BHK$1.16BHK$313MHK$181M
Free cash flowHK$1.40BHK$707M-HK$684M-HK$165M-HK$152M
Capital expenditureHK$1.43BHK$1.37BHK$1.63BHK$596MHK$451M
Total debtn/aHK$979MHK$528MHK$3.13MHK$86.7M

Quarterly statements and history in the cockpit →

WuXi XDC Cayman competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

+25%+50%+75%+100%0%+20%4523ICLRCRLMEDPPGNY2268.HK6-month return →1-month return →
Up and to the right = strong over both horizons. WuXi XDC Cayman is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%+30%+40%20×30×4523ICLRCRLMEDPPGNY2268.HKRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. WuXi XDC Cayman is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%0%50%100%4523ICLRCRLMEDPPGNY2268.HKGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. WuXi XDC Cayman is the large dot.

WuXi XDC Cayman competitors and peer comparison

Head to head with its named competitors (2268.HK vs 2269.HK vs LONN.SW vs 207940.KS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
WuXi XDC Cayman 2268.HK$10.4B+20%+42%28%35.8×20.6%
Wuxi Bio 2269.HK$23.1B+35%+22%32%26.5×20.8%
Lonza LONN.SW$53.9B+36%-11%25%36.1×15.6%
Samsung Biologics 207940.KS$48.7B-6%-20%43%34.4×7.0%

How WuXi XDC Cayman compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

WuXi XDC Cayman against its 5 peers (data as of 18 Nov 2026)
Measure2268.HKPeer medianRank in peer set
1-month return-12.9%+6.1%lowest of 6
6-month return+19.8%+53.3%2nd lowest of 6
Distance from 52-week high-22.8%-6.8%lowest of 6
Revenue growth (TTM)+41.5%+5.5%highest of 6
Operating margin27.7%9.6%highest of 6
Forward P/E35.8×26.2×most expensive of 6
Growth the price implies (Req g, 7 yrs)20.6%15.9%3rd most demanding of 6
Growth delivered (Del g)+126.4%+22.3%highest of 6
Hurdle (Req g minus delivered)-105.9 pp+0.0 ppleast demanding of 6
ROIC minus cost of capital+14.3 pp-2.0 pp2nd highest of 5
EV / EBITDA31.4×18.8×most expensive of 6
Net debt / EBITDA-2.5×-0.7×least indebted of 6

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
WuXi XDC Cayman 2268.HKHong Kong$10.4B+20%+42%28%35.8×20.6%+126.4%
Eisai 4523.TJapan$9.36B+11%+11%6%26.6×10.7%+5.0%
ICON ICLRUnited States$14.6B+70%+1%10%17.3×15.9%+24.2%
Charles River Laboratories CRLUnited States$16.0B+114%-1%15%26.2×25.6%+6.6%
Medpace MEDPUnited States$18.1B+53%+20%21%33.5×22.3%+22.3%
Progyny PGNYUnited States$2.66B+41%+6%9%23.2×8.6%+30.2%

Questions

Who are WuXi XDC Cayman's main competitors?
Named competitors: WuXi Biologics (2269.HK), Lonza (LONN.SW), Catalent (private or unlisted), Samsung Biologics (207940.KS). The cockpit's measured peer set (industry) also includes Eisai (4523.T), ICON (ICLR), Charles River Laboratories (CRL), Medpace (MEDP), Progyny (PGNY).
Is WuXi XDC Cayman expensive compared with its peers?
On forward p/e it trades at 35.8× against a peer median of 26.2×, most expensive of 6 in its peer set. For today's price to make sense, revenue must grow about 21% a year for seven years (Req g). Recent delivered growth is +126%, so the hurdle is -106 pp: the price already allows for a slowdown.
How has WuXi XDC Cayman stock performed?
Over six months to 18 Nov 2026 the shares returned +19.8% against +53.3% for the median peer; over one year -4.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.